SIRPA antagonism to enhance microglial activation through removal of inhibitory CD47-SIRPA signaling
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["CD47 Expression on Neurons and Plaques Anti-Phagocytic Do Not Eat Me Signal"]
B["SIRPA Receptor on Microglia Inhibitory Immunoreceptor"]
C["CD47-SIRPA Interaction Microglial Phagocytosis Suppressed"]
D["Amyloid and Debris Accumulate Clearance Impaired in Disease"]
E["SIRPA Antagonist Treatment Removes CD47-Mediated Inhibition"]
F["Microglial Phagocytic Activation Disinhibition of Clearance"]
G["Amyloid Plaque Burden Reduced Neuroinflammation Resolved"]
H["AD Neuroprotective Outcome Cognitive Preservation"]
A --> B
B --> C
C --> D
E -.->|"blocks inhibitory signal"| C
E --> F
F --> G
G --> H
style C fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations6 with PMID5 mediumValidation: 45%5 supporting / 1 opposing
✓For(5)
5
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
1
1
MECH 4CLIN 1GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Microglia regulation of synaptic plasticity and le…
Engineered Bacterial Outer Membrane Vesicles-Based Doxorubicin and CD47-siRNA Co-Delivery Nanoplatform Overcomes Immune Resistance to Potentiate the Immunotherapy of Glioblastoma.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-06 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Based on the information gathered about TREM2, its protein interactions, and pathways, I'll now generate novel therapeutic hypotheses for targeting TREM2 in Alzheimer's disease following the INVOKE-2 failure:
Novel Therapeutic Hypotheses for TREM2 in Alzheimer's Disease
Hypothesis 1: TYROBP-SYK Pathway Enhancement
Title: Selective TYROBP stabilization to bypass TREM2 ectodomain loss
Description: Given TREM2's obligate partnership with TYROBP (DAP12) for signaling, developing small molecule stabilizers of the TYROBP-SYK complex could maintain downstream neuroprotective signali
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
I'll critically evaluate each of these TREM2 therapeutic hypotheses by examining their weaknesses, counter-evidence, and proposing falsifying experiments.
Critical Evaluation of TREM2 Therapeutic Hypotheses
Hypothesis 1: TYROBP-SYK Pathway Enhancement
Specific Weaknesses:
Assumes TYROBP-SYK signaling is universally beneficial, ignoring potential inflammatory consequences
Overlooks that TYROBP is shared with multiple immune receptors (not TREM2-specific)
No consideration of dose-response relationships or therapeutic window
Counter-evidence: The literature shows that exce
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Based on my analysis of the therapeutic hypotheses and available clinical data, here's my practical feasibility assessment:
PRACTICAL FEASIBILITY ASSESSMENT
HYPOTHESIS 1: TYROBP-SYK PATHWAY ENHANCEMENT
Druggability: MODERATE
Existing compounds: Fostamatinib (SYK inhibitor, FDA-approved for ITP)
Chemical matter: Multiple SYK inhibitors exist (fostamatinib, entospletinib, TAK-659)
Target validation: Strong - SYK is highly druggable kinase with validated inhibitors
Competitive Landscape:
Rigel Pharmaceuticals (fostamatinib) - established SYK franchise
M
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Based on the comprehensive debate between the Theorist, Skeptic, and Expert, I'll synthesize their inputs and produce final scored rankings. Let me analyze the evidence and score each hypothesis across the 10 dimensions.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
💬 Discussion
Loading comments...
No DepMap CRISPR Chronos data found for ['SIRPA'].
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
IF primary mouse microglia are treated with SIRPA-blocking antibody (500 µg/mL) for 48 hours, THEN cell surface CD86 and CD68 expression will increase by ≥50% compared to isotype control, using cultured primary microglia from C57BL/6 mice.
pendingconf: 0.78
Expected outcome: CD86 MFI increases from baseline ~200 to ≥300; CD68+ area increases ≥50% via confocal morphometry; phagocytosis of fluorescent E. coli bioparticles increases ≥40%
Falsified by: No significant change (<20% increase) in CD68/CD86 expression or phagocytic index after SIRPA blockade would refute the hypothesis that SIRPA antagonism disinhibits microglial activation
Method: Flow cytometry quantification of activation markers (CD86, CD68, MHC-II) and fluorescent bead/bioparticle phagocytosis assay on FACS-purified CD11b+ microglia
IF anti-SIRPA antibody (10 mg/kg, i.p., every 3 days) is administered to 5xFAD transgenic mice for 4 weeks, THEN amyloid plaque burden will decrease by ≥30% in the hippocampus compared to vehicle-treated controls, using 5xFAD APP/PS1 mice at 6 months of age.
pendingconf: 0.72
Expected outcome: Congo red+ plaque area decreases ≥30% in hippocampus; Iba1+ microglia show hypertrophic morphology (somatic area ≥150% of control); CD68+ microglial coverage around plaques increases ≥40%
Falsified by: No reduction in amyloid burden or failure to observe morphologically activated microglia after SIRPA antagonist treatment would disprove the hypothesis that SIRPA blockade enhances microglial-mediated clearance in vivo
Method: Stereological quantification of amyloid plaques via histology; morphological Sholl analysis of Iba1+ microglia; spatial analysis of microglial plaque association in 5xFAD mice
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
['SIRPA'] — Search for structure
Click to search RCSB PDB